167096-99-3

Basic information

• Product Name: (3S,4R)-BENZYL 3,4-DIHYDROXYPIPERIDINE-1-CARBOXYLATE
• Synonyms: (3S,4R)-BENZYL 3,4-DIHYDROXYPIPERIDINE-1-CARBOXYLATE;Benzyl (3S,4R)-3,4-dihydroxypiperidine-1-carboxylate;1-Piperidinecarboxylic acid, 3,4-dihydroxy-, phenylMethyl ester, (3R,4S)-rel-;RNUMISHXYWFZCE-NEPJUHHUSA-N
• CAS NO: 167096-99-3
• Molecular Formula: C13H17NO4
• Molecular Weight: 251.28
• Mol File: 167096-99-3.mol

Chemical Properties

• Boiling Point: 410.363°C at 760 mmHg
• Flash Point: 201.98°C
• Appearance: /
• Density: 1.324g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.604
• PKA: 14.21±0.40(Predicted)
• CAS DataBase Reference: (3S,4R)-BENZYL 3,4-DIHYDROXYPIPERIDINE-1-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: (3S,4R)-BENZYL 3,4-DIHYDROXYPIPERIDINE-1-CARBOXYLATE(167096-99-3)
• EPA Substance Registry System: (3S,4R)-BENZYL 3,4-DIHYDROXYPIPERIDINE-1-CARBOXYLATE(167096-99-3)

Safety Data

• Hazardous Substances Data: 167096-99-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(3S,4R)-Benzyl 3,4-dihydropyridine-1-carboxylate is used as a building block in organic synthesis for the creation of complex organic molecules. Its unique structure and stereochemistry allow for the development of novel compounds with specific properties and functions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (3S,4R)-Benzyl 3,4-dihydropyridine-1-carboxylate is utilized as an intermediate in the synthesis of pharmaceuticals. Its presence in the molecular structure of target compounds can contribute to their therapeutic effects, making it a key component in drug discovery and development processes.
Used in Drug Discovery:
(3S,4R)-Benzyl 3,4-dihydropyridine-1-carboxylate is employed in drug discovery as a valuable molecule for research. Its unique stereochemistry and structural features make it an attractive candidate for the exploration of new drug targets and the advancement of existing therapeutic agents.
Used in Pharmaceutical Industry:
Within the pharmaceutical industry, (3S,4R)-Benzyl 3,4-dihydropyridine-1-carboxylate is used as a key component in the development of new drugs. Its incorporation into drug molecules can enhance their efficacy, selectivity, and pharmacokinetic properties, ultimately contributing to improved patient outcomes.
Used in Bioactive Compounds Synthesis:
(3S,4R)-Benzyl 3,4-dihydropyridine-1-carboxylate is also used in the synthesis of bioactive compounds, which are molecules that interact with biological systems to produce a therapeutic effect. Its unique structure and stereochemistry can be leveraged to create bioactive compounds with specific biological activities, broadening the scope of available treatments for various diseases and conditions.

InChI:InChI=1/C13H17NO4/c15-11-6-7-14(8-12(11)16)13(17)18-9-10-4-2-1-3-5-10/h1-5,11-12,15-16H,6-9H2/t11-,12+/m1/s1

Upstream product

• 501-53-1 benzyl chloroformate 
• 66207-23-6 1-benzyloxycarbonyl-1,2,3,6-tetrahydropyridine 
• 443648-89-3 (-)-(3R,4R)-3,4-dihydroxypiperidine hydrochloride 
• 886847-37-6 (3R,4R)-3-acetoxy-1-benzyloxycarbonyl-4-hydroxypiperidine 
• 694-05-3 1,2,3,6-tetrahydropyridine 
• 66207-08-7 3,4-epoxy-piperidine-1-carboxylic acid benzyl ester 
• 266688-40-8 5-amino-4,5-dideoxy-D-threo-pentono-1,5-lactam 
• 266688-37-3 methyl 4-cyano-4-deoxy-D-threonate 
• 266688-39-5 5-amino-2,3-di-O-acetyl-4,5-dideoxy-D-threo-pentono-1,5-lactam 
• 266688-38-4 methyl 2,3-di-O-acetyl-4-cyano-4-deoxy-D-threonate 
• 37088-07-6 1,4,5-trideoxy-1,5-imino-D-threo-pentitol 
• 1624258-63-4 rac-benzyl 7-oxa-3-azabicyclo[4.1.0]heptane-3-carboxylate 
• 108-05-4 vinyl acetate 
• 167096-99-3 (+/-)-trans-1-benzyloxycarbonyl-3,4-dihydroxypiperidine 

Downstream Products

• 37088-07-6 1,4,5-trideoxy-1,5-imino-D-threo-pentitol 
• 37088-07-6 (3S,4R)-piperidine-3,4-diol 
• 1247884-87-2 3,4-diazidopiperidine-1-carboxylic acid benzyl ester 
• 1247884-89-4 benzyl 3,4-diaminopiperidine-1-carboxylate 

Relevant articles and documents

BETA-LACTAMASE INHIBITORS

Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS

The invention relates to bicyclic compounds of formulas I and I', and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

Glycosynthase-Mediated Assembly of Xylanase Substrates and Inhibitors

An exo-β-xylosidase mutant with glycosynthase activity was created to aid in the synthesis of xylanase substrates and inhibitors. Simple monosaccharides were easily elaborated into di-, tri- and tetrasaccharides by using this enzyme. Some products proved

Bicyclic carbamates as inhibitors of papain-like cathepsin proteases

A 6-oxa-1-aza-bicyclo[3.2.1]octan-7-one system inhibits the proteolytic activity of several cysteine proteases belonging to the papain family. In vitro mechanistic studies and in silico calculations suggest that the minimal π-overlap between the bridgehea

Biocatalytic preparation of enantioenriched 3,4-dihydroxypiperidines and theoretical study of Candida antarctica lipase B enantioselectivity

Enzymatic acetylations of N-substituted cis- and trans-3,4- dihydroxypiperidine and hydrolysis of their diacetylated derivatives have been studied. High enantioselectivities are obtained with Pseudomonas cepacia lipase and Candida antarctica lipase B for

CHEMOKINE RECEPTOR ANTAGONISTS

A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof, wherein the variants R, R9, Z, X, Q and Y are defined in the specification.

MODULATORS OF CELLULAR ADHESION

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

Enantioselective Trans Dihydroxylation of Nonactivated C-C Double Bonds of Aliphatic Heterocycles with Sphingomonas sp. HXN-200

The bacterial strain Sphingomonas sp. HXN-200 was used to catalyze the trans dihydroxylation of N-substituted 1,2,5,6-tetrahydropyridines 1 and 3-pyrrolines 4 giving the corresponding 3,4-dihydroxypiperidines 3 and 3,4-dihydroxypyrrolidines 6, respectivel

Stereoelectronic substituent effects in polyhydroxylated piperidines and hexahydropyridazines

From the pKa values of the conjugate acids of a large series of hydroxylated piperidines and hexahydropyridazines, a consistent difference in basicity was found between stereo-isomers having an axial or equatorial hydroxyl (OH) group either β o

Nanomolar versus millimolar inhibition by xylobiose-derived azasugars: Significant differences between two structurally distinct xylanases

The synthesis of xylobiose-derived nitrogen-containing inhibitors of xylanase is described starting with accessible precursors through efficient synthetic schemes. Four disaccharides were identified as powerful competitive inhibitors of the retaining fami